Skip to content

Study · Randomized controlled trial · n = 44 · 2015

3 results

Liraglutide treatment causes upregulation of adiponectin and downregulation of resistin in Chinese type 2 diabetes.

Li D, Xu X, Zhang Y, Zhu J, Ye L, Lee KO, Ma J

Diabetes research and clinical practice6 Jun 2015Cited by 34 (Europe PMC)

PMID26376464 (opens in a new tab)DOI10.1016/j.diabres.2015.05.051 (opens in a new tab)PepBankPUB-26376464
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Chinese adults with type 2 diabetes on metformin, plasma adiponectin rose with liraglutide compared with glimepiride.

    In plain wordsIn Chinese adults with type 2 diabetes, liraglutide raised the blood level of adiponectin compared with glimepiride.

    Peptide
    Liraglutide
    Outcome
    IncreasePlasma adiponectin
    Study

    n = 44

    Comparator
    Glimepiride
    Outcome group
    Adipokines · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Measurements

    Adiponectin change
    0.74 ng/ml
    liraglutide
    Adiponectin change
    −0.44 ng/ml
    glimepiride

    Source sentences

    Summary
    The plasma level of adiponectin was significantly increased (0.74±0.19 ng/ml, p<0.05) and resistin was significantly lowered (-1.34±0.34 pg/ml, p<0.05) in a dose-dependent manner in the liraglutide group when compared with the glimepiride group (-0.44±0.09 ng/ml of adiponectin and 0.14±0.41 pg/ml of resistin).
    2 context sentences
    Summary · context
    Forty-four subjects were recruited and randomly assigned to once-a-day dosage of either liraglutide, or glimepiride (4 mg) in a double-blinded double-dummy active-controlled study.
    Summary · context
    All treatments were administered in combination with metformin (1 g, twice daily).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Chinese adults with type 2 diabetes on metformin, plasma resistin fell with liraglutide compared with glimepiride.

    In plain wordsIn Chinese adults with type 2 diabetes, liraglutide lowered the blood level of resistin compared with glimepiride.

    Peptide
    Liraglutide
    Outcome
    DecreasePlasma resistin
    Study

    n = 44

    Comparator
    Glimepiride
    Outcome group
    Adipokines · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Measurements

    Resistin change
    −1.34 pg/ml
    liraglutide
    Resistin change
    0.14 pg/ml
    glimepiride

    Source sentences

    Summary
    The plasma level of adiponectin was significantly increased (0.74±0.19 ng/ml, p<0.05) and resistin was significantly lowered (-1.34±0.34 pg/ml, p<0.05) in a dose-dependent manner in the liraglutide group when compared with the glimepiride group (-0.44±0.09 ng/ml of adiponectin and 0.14±0.41 pg/ml of resistin).
    2 context sentences
    Summary · context
    Forty-four subjects were recruited and randomly assigned to once-a-day dosage of either liraglutide, or glimepiride (4 mg) in a double-blinded double-dummy active-controlled study.
    Summary · context
    All treatments were administered in combination with metformin (1 g, twice daily).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Chinese adults with type 2 diabetes on metformin, the decrease in HbA1c did not differ between liraglutide and glimepiride.

    In plain wordsIn Chinese adults with type 2 diabetes, HbA1c fell by a similar amount with liraglutide and glimepiride.

    Peptide
    Liraglutide
    Outcome
    No significant changeHbA1c decrease
    Study

    n = 44

    Comparator
    Glimepiride
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Measurements

    HbA1c after treatment
    7.2%
    liraglutide
    HbA1c after treatment
    7.3%
    glimepiride

    Source sentences

    Summary
    In contrast, we found no differences in the decrease in HbA1c between the two groups (8.3±1.2% to 7.2±1.1% in NGSP units vs. 8.3±1.0% to 7.3±1.2% in NGSP units; 67±13 mmol/mol to 55±12 mmol/mol vs. 67±11 mmol/mol to 56±13 mmol/mol in IFCC units).
    2 context sentences
    Summary · context
    Forty-four subjects were recruited and randomly assigned to once-a-day dosage of either liraglutide, or glimepiride (4 mg) in a double-blinded double-dummy active-controlled study.
    Summary · context
    All treatments were administered in combination with metformin (1 g, twice daily).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.